Overexpression of CD24, c-myc and Phospholipase 2A in Prostate Cancer Tissue Samples Obtained by Needle Biopsy



Altered CD24, c-myc and phospholipase 2a expression was reported in different cancers. Our aim was to measure the expression of these genes in prostate cancer tissues, and compare it to non-cancerous samples. Prostate tissue samples were collected by needle biopsy from 20 prostate cancer (PCA) and 11 benign prostate hyperplasic (BPH) patients. RNA was isolated; cDNA synthetized, CD24, c-myc and phospholipase 2A (PL2A) expressions were determined by quantitative real-time PCR method. The expression of β-globin gene was measured for normalization of the gene expression results. Serum prostate specific antigen (PSA) levels were determined by microparticle enzyme immunoassay (MEIA) method. PSA levels were significantly different between the PCA and BPH groups, 252.37 ± 308.33 ng/ml vs. 3.5 ± 2.14 ng/ml (p = 0.001), respectively. CD24 expression was 988.86 ± 3041 ng/μl in prostate tumor and 4.00 ± 4.25 ng/μl in the BPH group (p = 0.035). The c-myc expression was 88.32 ± 11.93 ng/μl in the prostate tumor and 17.08 ± 21.75 ng/μl in the BPH group (p = 0.02), and the PL2A 31.36 ± 67.02 ng/μl was in PCA and 5.56 ± 14.08 ng/μl in BPH (p = 0.025). Gleason’s scores showed correlation with c-myc (p = 0.019) and PSA (p = 0.033) levels. Overexpression of PL2A, CD24 and c-myc was observed in prostate cancer samples using quantitative real-time PCR method.


Prostate cancer Gene expression CD24 c-myc Phospholipase 2A 


  1. 1.
    Müller H, Brenner H (2006) Urine markers as possible tools for prostate cancer screening: review of performance characteristics and practicality. Clin Chem 52:562–573PubMedCrossRefGoogle Scholar
  2. 2.
    Kopper L, Timár J (2005) Genomics of prostate cancer: is there anything to “translate”. Pathol Oncol Res 11:197–203PubMedCrossRefGoogle Scholar
  3. 3.
    Maitland NJ, Collins A (2005) A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int 96:1219–1223PubMedCrossRefGoogle Scholar
  4. 4.
    Hughes C, Murphy A, Martin C et al (2005) Molecular pathology of prostate cancer. J Clin Pathol 58:673–684PubMedCrossRefGoogle Scholar
  5. 5.
    Quinn DI, Henshall SM, Sutherland LR (2005) Molecular markers of prostate cancer outcome. Eur J Cancer 41:858–887PubMedCrossRefGoogle Scholar
  6. 6.
    Glinsky VG, Glinskii BA, Stephenson JA et al (2004) Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 113:913–923PubMedGoogle Scholar
  7. 7.
    Prowatke I, Devens F, Benner A et al (2006) Expression analysis of imbalanced genes in prostate carcinoma using tissue microarrays. Br J Cancer 96:82–88PubMedCrossRefGoogle Scholar
  8. 8.
    Nupponen NN, Kakkola L, Koivisto P et al (1998) Genetic alterations in hormone refractory recurrent prostate carcinomas. Am J Pathol 153:141–148PubMedGoogle Scholar
  9. 9.
    Kristiansen G, Denkert C, Schlüns K et al (2002) CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patients survival. Am J Pathol 161:1215–1221PubMedGoogle Scholar
  10. 10.
    Kristiansen G, Schlüns K, Yongwei Y et al (2003) CD24 is an independent prognostic marker of survival in non-small cell lung cancer patients. Br J Cancer 88:231–236PubMedCrossRefGoogle Scholar
  11. 11.
    Kristiansen G, Winzer KJ, Mayordomo E et al (2003) CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9:4906–4913PubMedGoogle Scholar
  12. 12.
    Kristiansen G, Pilarsky C, Pervan J et al (2004) CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 58:183–192PubMedCrossRefGoogle Scholar
  13. 13.
    Ponzielli R, Katz S, Barsyte-Lovejoy D et al (2005) Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 41:2485–2501PubMedCrossRefGoogle Scholar
  14. 14.
    Devi RG, Oldenkamp RJ, London AC et al (2002) Inhibition of human chorionic gonadotropin β-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 53:200–210PubMedCrossRefGoogle Scholar
  15. 15.
    Hirabayashi T, Shimuzu T (2000) Localization and regulation of cytosolic phospholipase A2. Biochim Biophys Acta 1488:124–138PubMedGoogle Scholar
  16. 16.
    Dong Q, Patel M, Scott KF et al (2006) Oncogenic action of phospholipase A2 in prostate cancer. Cancer Letters 240:9–16PubMedCrossRefGoogle Scholar
  17. 17.
    Wikmam H, Seppanen JK, Sarhadi VK et al (2004) Caveolins as tumor markers in lung cancer detected by combined use of cDNA and tissue microarrays. J Pathol 203:584–593CrossRefGoogle Scholar
  18. 18.
    Kettunen E, Nicholson AG, Nagy B et al (2005) L1CAM, INP10, P-cadherin, tPA and ITGB4 overexpression in malignant pleural mesothelioma primary tumors revealed by combined use of cDNA and tissue microarray. Carcinogenesis 26:17–25PubMedCrossRefGoogle Scholar
  19. 19.
    Schostak M, Krause H, Miller K et al (2006) Quantitative real-time RT-PCR of CD24 mRNA in the detection of prostate cancer. BMC Urol 119:1396–1402Google Scholar
  20. 20.
    Nagy B, Lundan T, Larramendy ML et al (2003) Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma. Br J Haematol 120:434–441PubMedCrossRefGoogle Scholar
  21. 21.
    Ohl F, Jung M, Xu C et al (2005) Gene expression studies in prostate cancer tissue: with reference gene should be selected for normalization? J Mol Med 83:1014–1024PubMedCrossRefGoogle Scholar
  22. 22.
    Calvo A, Gonzalez-Moreno O et al (2005) Prostate cancer and the genomic revolution: advances using microarray analyses. Mut Res 576:66–79Google Scholar
  23. 23.
    Raife TJ, Lager DJ, Kemp JD et al (1994) Expression of CD24 (BA-1) predicts monocytic lineage in acute myeloid leukemia. Am J Clin Pathol 101:296–299PubMedGoogle Scholar
  24. 24.
    Jackson D, Waibel R, Weber E et al (1992) CD24, a signal-transducing molecule expressed on human B cells, is a major surface antigen on small cell lung carcinomas. Cancer Res 52:5264–5270PubMedGoogle Scholar
  25. 25.
    Huang LR, Hsu HC (1995) Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 55:4717–4721PubMedGoogle Scholar
  26. 26.
    Pirrucello SJ, Lang MS (1990) Differential expression of CD24-related epitopes in mycosis fungiodes/Sezary syndrome: a potential marker for circulating Sezary cells. Blood 76:895–905Google Scholar
  27. 27.
    Jenkins RB, Qian J, Lieber MM et al (1997) Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57:524–531PubMedGoogle Scholar
  28. 28.
    Bernard D, Pourtuer-Manzanedo A, Gil J et al (2003) Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 112:1724–1731PubMedGoogle Scholar
  29. 29.
    Shachaf CM, Kopelman AM, Arvanitis C et al (2004) MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431:1112–1117PubMedCrossRefGoogle Scholar
  30. 30.
    Arnold I, Watt FM (2001) c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol 11:558–568PubMedCrossRefGoogle Scholar
  31. 31.
    Liu YA, Roudier PM, True DL (2004) Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 165:1543–1556PubMedGoogle Scholar
  32. 32.
    Hughes-Fulford M, Tjandrawinata RR, Li C-F et al (2005) Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells. Carcinogenesis 26:1520–1526PubMedCrossRefGoogle Scholar
  33. 33.
    Kallajoki M, Alanen KA, Nevalainen M et al (1998) Group II phospholipase A2 in human male reproductive organs and genital tumors. Prostate 35:263–272PubMedCrossRefGoogle Scholar
  34. 34.
    Shimuzu M, Matsumoto Y, Kurosawa T et al (2008) Release of arachidonic acid induced by tumor necrosis factor-α in the presence of caspase inhibition: evidence for cytosolic phospholipase A2α-independent pathway. Biochem Pharmacol doi:10.1016/j.bcp.2007.11.020
  35. 35.
    Cummings BS (2007) Phospholipase A2 as targets for anticancer drugs. Biochem Pharmacol 74:949–959PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2008

Authors and Affiliations

  1. 1.Genetic Laboratory, 1st Department of Obstetrics and GynecologySemmelweis UniversityBudapestHungary
  2. 2.Department of UrologySemmelweis UniversityBudapestHungary
  3. 3.BudapestHungary

Personalised recommendations